Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer.

Saved in:
Bibliographic Details
Title: Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer.
Authors: Raizenne BL; Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Koshkin VS; Division of Hematology/Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Zhu A; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Ben-David R; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Dufault SM; Division of Biostatistics, Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA., Eraky A; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Friedlander TW; Division of Hematology/Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Hong JC; Department of Radiation Oncology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Wong AC; Department of Radiation Oncology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Chou J; Division of Hematology/Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Chu C; Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Mar N; Division of Hematology and Oncology, Irvine Medical Center, University of California, Orange, CA., Ma TM; Department of Radiation Oncology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA., Sfakianos JP; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Porten S; Department of Urology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA., Seyedin SN; Division of Biostatistics, Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA. Electronic address: steven.seyedin@ucsf.edu.
Source: Clinical genitourinary cancer [Clin Genitourin Cancer] 2026 Jun; Vol. 24 (4), pp. 102524. Date of Electronic Publication: 2026 Feb 21.
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1938-0682
DOI:10.1016/j.clgc.2026.102524